Minoxidil
Rogaine (topical) / oral minoxidil
Minoxidil (Rogaine (topical) / oral minoxidil) is a hormonal & sexual research compound. Potassium channel opener and vasodilator. It lengthens the anagen (growth) phase and increases follicle size. Notably it does nothing to DHT — it's a growth stimulus, not an androgen blocker, which is why it stacks with finasteride rather than duplicating it.
Minoxidil quick facts
| Reported research dose (Oral) | Topical 5% twice daily; oral 0.625–5mg daily |
| Route | Topical or oral |
| Frequency | 1–2x |
| Half-life | ~4 hours oral |
| Forms | Oral, Topical |
| Evidence level | Large RCTs for topical; a growing trial base for low-dose oral |
| Other forms available | Topical — dosed differently |
Expect shedding in the first 4–8 weeks — that's synchronized follicles entering a new growth phase, it's a sign it's working, and it's the reason most people quit too early. Topical needs sulfotransferase in the scalp to activate; low responders often do far better on oral. ⚠️ Oral minoxidil can cause fluid retention, ankle edema and pericardial effusion at higher doses — it needs a prescriber and BP monitoring.
How Minoxidil works
Potassium channel opener and vasodilator. It lengthens the anagen (growth) phase and increases follicle size. Notably it does nothing to DHT — it's a growth stimulus, not an androgen blocker, which is why it stacks with finasteride rather than duplicating it.
Proposed benefits
Hair density and regrowth — a vasodilator that lengthens the growth phase of the follicle. It does nothing to DHT, which is why it is stacked with finasteride rather than swapped for it.
Where to get Minoxidil
Buy Minoxidil at AlgoRx →The evidence for Minoxidil
Graded by what exists behind each claim.
✅ Clinically validated
- Approved and heavily trialed for androgenetic alopecia, topically. Oral low-dose minoxidil now has substantial published clinical series and increasingly randomized data showing efficacy, often exceeding topical.
- Originally an antihypertensive — the hair growth was the side effect that became the product.
📊 Correlative data
- Enormous real-world use. The consistent reports: an initial shedding phase at 2–8 weeks that alarms people and is expected, and for oral use, ankle edema and increased body hair as the dose rises.
🧪 Theoretical / extrapolated
- A potassium-channel opener and vasodilator. In the follicle it is thought to prolong the anagen (growth) phase and increase perifollicular blood flow.
- It requires sulfotransferase in the scalp to become the active minoxidil sulfate — which is the best explanation for non-responders, and the reason oral dosing works for some people topical never did.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Minoxidil actually does
Minoxidil is a prodrug, and almost everything confusing about it follows from that one fact. The molecule you apply to your scalp is not the molecule that grows hair. It has to be converted to minoxidil sulfate, and the enzyme that does it is sulfotransferase SULT1A1, expressed in the outer root sheath of the hair follicle itself Pietrauszka 2022. Not in the liver, for the topical route — in the follicle. The drug activates itself at the target, or it does not activate at all.
That is why response is bimodal rather than graded. Follicular SULT1A1 activity varies several-fold between people and is genetically and environmentally determined. A person with low follicular sulfotransferase applies a full dose, converts little of it, and gets nothing — and there is no way to tell that from "it has not worked yet" without measuring. Goren 2014 developed an enzymatic assay on plucked hairs that predicts response before treatment, and Pietrauszka 2022 reviews the enzyme as a prognostic marker. A commercially available test that tells you whether a drug will work on you, for a drug taken by millions, and almost nobody uses it.
What minoxidil sulfate does once it exists. It opens ATP-sensitive potassium channels — the Kir6.x/SUR2 complex — letting potassium out and hyperpolarizing the cell. In vascular smooth muscle that closes voltage-gated calcium channels and produces vasodilation, which is what the drug was originally licensed for as an antihypertensive. In the follicle the same channel opening is associated with prolongation of anagen, the growth phase, and with an increase in follicle size, alongside increased dermal papilla VEGF expression and local perfusion.
The shed is the mechanism working, and it is arithmetic. Hair cycles through anagen, catagen and telogen. A drug that pushes resting follicles into a new growth phase must first eject the club hairs sitting in them, and it does so in a synchronized wave because the drug arrives all at once. The shedding at weeks 4 to 8 is telogen follicles being recruited into anagen, which is the intended effect appearing as its opposite, and it is the single most common reason people stop before the drug has had a chance.
What it explicitly does not do: touch androgens. No 5-alpha-reductase inhibition, no androgen receptor binding, no effect on DHT. Minoxidil is a growth stimulus applied against an ongoing androgenic miniaturization process, which is why it is complementary to a 5-alpha-reductase inhibitor rather than redundant with one, and why stopping returns the follicle to whatever the androgen environment was doing to it Gupta 2022.
And the reason oral works for topical non-responders. Oral minoxidil is sulfated systemically rather than depending on the follicle's own enzyme, so circulating minoxidil sulfate reaches the follicle already activated. A low follicular SULT1A1 phenotype is a topical problem, not a minoxidil problem, and that is a mechanistic prediction the clinical experience has borne out.
Cell, rodent, human — and where it stops
Step one, topical, in humans: among the best-evidenced treatments in dermatology. Decades of randomized trials in androgenetic alopecia, and a modern synthesis: Gupta 2022 is a network meta-analysis in JAMA Dermatology comparing minoxidil against the 5-alpha-reductase inhibitors in male patients. This is regulatory-grade evidence and it is the reason this compound sits in a different class from most of this Vault. Zaky 2023 extends the comparison into a different site, testing topical minoxidil against topical bimatoprost.
Step two, the pharmacogenetic layer, which is where the interesting work is. Goren 2014 describes an enzymatic assay on plucked hair follicles that predicts minoxidil response before a person starts; Pietrauszka 2022 reviews follicular SULT1A1 activity as a prognostic marker for treatment. This is a worked-out biomarker for a common drug, published, validated, and essentially unused in practice.
Step three, low-dose oral, which is the fast-moving part. Vano-Galvan 2021 is the largest safety series: 1,404 patients — 943 women and 461 men, mean age 43, range 8 to 86 — treated for at least 3 months, with 2,469 dose-titration cases analyzed. The most common adverse effect was hypertrichosis at 15.1%, causing 14 discontinuations. Systemic effects were uncommon: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital edema 0.3%, insomnia 0.2%. Total discontinuations for adverse events: 29, or 1.2%. The authors conclude low-dose oral minoxidil has a good safety profile for hair loss.
Step four, the counterweight, published in the same period. Trueb 2022 is a case report of a serious complication of low-dose oral minoxidil for hair loss. One case against 1,404 patients is exactly the right ratio to hold in mind: the drug is well tolerated at population level and the rare serious event is real, and a percentage cannot tell an individual which side of it they are on.
The obstacles, named one at a time. (1) The 1,404-patient series is retrospective Vano-Galvan 2021 — strong for common adverse effects, weak for rare ones, and it does not measure efficacy. (2) Oral minoxidil is being used for hair loss entirely off-label; its licensed indication is severe refractory hypertension at much higher doses, where the label carries warnings about pericardial effusion and reflex tachycardia. (3) The SULT1A1 assay is not routinely available despite being published a decade ago. (4) Almost all efficacy data is in androgenetic alopecia; other hair-loss diagnoses respond differently or not at all, and the diagnosis is what determines that.
What would have to be true, and how you would know it was not
Three predictions. The first identifies the people for whom no hair drug will work until something else is fixed.
1. Draw ferritin, TSH and a CBC before blaming the drug. The three most common medical causes of hair shedding that no follicle-directed drug will overcome are iron deficiency, thyroid dysfunction and anemia. Ferritin is the iron measure that matters here and the thresholds used in hair medicine are higher than a laboratory's flag for anemia; TSH catches the thyroid; a CBC catches the anemia and gives the red cell indices. A person with a ferritin of 15 who is failing minoxidil does not have a minoxidil problem, and this is the most commonly missed thing on the whole subject.
2. The prediction that cuts against the product: this drug does nothing to the cause, and DHT is how you show it. Minoxidil does not alter DHT and does not touch androgen signaling Gupta 2022. So the mechanistic prediction is that androgenic miniaturization continues underneath a drug that is stimulating growth on top of it, and that stopping returns the follicle to its untreated trajectory within months. Minoxidil buys growth; it does not buy time. A person choosing minoxidil alone should know they are treating the output and not the driver, and a DHT measurement is the honest way to see the driver is still running.
3. If you take it orally, a CMP has a specific job. The systemic effects at population scale are uncommon Vano-Galvan 2021 and the mechanism — potassium channel opening and vasodilation — is one that moves fluid, electrolytes and heart rate. A CMP at baseline and after a few months covers sodium, potassium and creatinine, and resting heart rate measured the same way each morning is the other half. Ankle swelling and unexplained shortness of breath are the symptoms that mean stop and be seen, not measure again Trueb 2022.
What nobody has tested yet
Four things that remain unsettled about one of the most-used drugs in dermatology.
Nobody has made the SULT1A1 test routine. The assay is published, uses plucked hairs, and predicts response Goren 2014 Pietrauszka 2022. A trial that randomized people to test-guided treatment against standard treatment, with adherence at 12 months as the endpoint, would establish whether knowing in advance stops people abandoning a drug that was never going to work for them. It has not been run.
Nobody has tested whether topical non-responders are oral responders, prospectively. The mechanism predicts it clearly: systemic sulfation bypasses the follicular enzyme. The design is obvious — enroll assay-confirmed low-SULT1A1 topical non-responders, give oral, measure hair counts — and the result would either confirm the whole prodrug model in humans or break it.
Nobody has established the lowest effective oral dose. The 1,404-patient series analyzed 2,469 dose-titration cases Vano-Galvan 2021, which is a rich dataset for adverse effects by dose and not a dose-response for efficacy. Since hypertrichosis at 15.1% is the main reason people stop, and it is dose-related, the minimum effective dose is the number that would most improve real outcomes.
Nobody has run a topical-versus-oral head-to-head with the enzyme assay built in. That single trial would answer the efficacy question, the route question and the pharmacogenetic question at once, and it is the most obvious missing study in the field.
Minoxidil — its own safety story, not its class's
Minoxidil has a real label, a real safety literature and a real adverse-effect profile, so the generic caution block above is the wrong instrument. Here is what the numbers say.
Topical and oral are different risk propositions. Topical absorption is on the order of a few percent, and the adverse effects are overwhelmingly local — irritation, contact dermatitis, and facial hypertrichosis from the solution running where it is not wanted. Propylene glycol in the older solutions is the usual irritant, and foam formulations exist because of it.
Oral: the honest numbers, from 1,404 patients. Hypertrichosis 15.1% — the effect people most often stop for — then lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital edema 0.3% and insomnia 0.2%, with 1.2% discontinuing overall Vano-Galvan 2021. Set those beside Trueb 2022, a case report of a serious complication. Both are true at once.
The mechanism explains the cardiovascular list, which is why the list is predictable. Vasodilation lowers peripheral resistance; the body compensates with reflex tachycardia and with renal sodium and water retention. That is the pathway to edema and, at the high antihypertensive doses in the original label, to pericardial effusion. Low-dose use for hair is a fraction of those doses, and it is the same pharmacology at a lower point on the same curve — which is the accurate way to hold it, rather than as either a different drug or the same risk.
Who should not start oral without a prescriber. Anyone with known cardiac disease, existing fluid retention, or on other antihypertensives, where the additive effect is the issue. The hair-loss dose requires a prescriber precisely because the drug it is a low dose of is a potent antihypertensive.
Two practical points that are not on any label. Hair grows where the drug goes, so a topical that migrates onto the face produces hair on the face — the single most common reason women discontinue. And oral minoxidil in a household with pets is worth handling carefully; minoxidil is seriously toxic to cats, and a spilled solution is the realistic exposure route.
Sources read for this page
- Gupta AK, et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatology 2022 · PMID 35107565
- Vano-Galvan S, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology 2021 · PMID 33639244
- Trueb RM, et al. Serious complication of low-dose oral minoxidil for hair loss. JAAD Case Reports 2022 · PMID 36425662
- Pietrauszka K, Bergler-Czop B. Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Postepy Dermatologii i Alergologii 2022 · PMID 35950120
- Goren A, et al. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy 2014 · PMID 24283387
Minoxidil — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Applied to scalp, systemic exposure is low but not zero — and the predicted problems are the ones that occur when it is not zero.
- Minoxidil is a vasodilator, so the predicted systemic effects are dose-dependent: lowered blood pressure, tachycardia, fluid retention and ankle swelling. Oral minoxidil produces these reliably; topical produces them in people who use a lot, on damaged skin, or who absorb unusually well.
- Unwanted hair growth away from the scalp is the predictable consequence of a systemic hair-growth signal, and it is the most common reason people stop.
- The shed in the first weeks is expected — minoxidil pushes follicles into a new growth phase and the old hairs release first. Stopping because of it is the classic mistake.
What has actually been reported
- Contact dermatitis and scalp irritation are common, and are more often the propylene glycol vehicle than the drug — foam formulations exist for exactly that reason.
- Ketoconazole shampoo is well tolerated; the main issue is dryness.
How to reduce the risk
Same mechanism as the prediction.
- Apply to a dry scalp, not broken or freshly microneedled skin — absorption through compromised skin is the situation where a topical starts behaving systemically.
- Switch to foam if the vehicle is irritating rather than abandoning the drug.
- Any of this stops working when you stop using it. That is the mechanism, not a failure — the effect requires continued signal.
What it does to your bloodwork
A fact about the assay.
- Nothing routine for topical use. Blood pressure and resting heart rate if you are using a large volume or have moved to oral.
Don't run this if
- You have a cardiovascular condition and are considering ORAL minoxidil — that is a prescriber's decision, and it was a blood pressure drug before it was a hair drug.
- You have cats in the house. Minoxidil is severely toxic to them and residue transfer is a documented cause of death.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Minoxidil — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Minoxidil moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Minoxidil in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Minoxidil
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Total Testosterone | The baseline you can't reconstruct later |
| Free Testosterone | The fraction that does anything — total alone misleads |
| SHBG (Sex Hormone-Binding Globulin) | Explains a normal total sitting on top of a low free |
| Estradiol, Sensitive (LC/MS-MS) | The other half of the ratio, and the source of most symptoms |
| LH & FSH | Separates a testicular problem from a pituitary one |
The “Low T? Rule Out the Reversible Causes First” panel covers these in one order — 11 markers, $211.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Minoxidil — frequently asked questions
What is Minoxidil?
Minoxidil (Rogaine (topical) / oral minoxidil) is a hormonal & sexual research compound. Potassium channel opener and vasodilator. It lengthens the anagen (growth) phase and increases follicle size. Notably it does nothing to DHT — it's a growth stimulus, not an androgen blocker, which is why it stacks with finasteride rather than duplicating it.
Is the full Minoxidil protocol on this page?
The reported research dose is on this page, along with how Minoxidil works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Minoxidil?
Minoxidil has an approximate half-life of ~4 hours oral, which is part of what determines how often it's dosed.
What forms does Minoxidil come in?
Minoxidil is available as: Oral, Topical.
What's the evidence behind Minoxidil?
Current evidence level: Large RCTs for topical; a growing trial base for low-dose oral. Minoxidil is offered for research purposes only and is not an approved medicine.
Minoxidil inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Minoxidil is used for
Minoxidil appears under 2 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Minoxidil is the dht & hair arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.